We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $211M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.09.2020 | Series C | $85M | - |
| 11.03.2020 | Series B | $78.5M | - |
| 23.09.2018 | Series A | $47.5M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 30.11.2020 | Seattle biotech firm Silverback Therapeutics sets terms for ... | Laura Shawver, CEO of Silverback Therapeutics. (Silverback Photo) Silverback Therapeutics plans to ... | geekwire.c... |
| 23.09.2020 | Silverback Therapeutics Raises $85 Million in Series C Finan... | - | orbimed.co... |
| 23.09.2020 | Silverback Therapeutics Raises $85M in Series C | SEATTLE, WA, Silverback Therapeutics announced the close of an $85 million Series C financing roun... | vcnewsdail... |
| 23.09.2020 | Silverback Therapeutics Raises $85 Million in Series C Finan... | - | usvp.com/n... |
| 23.09.2020 | Silverback Therapeutics Raises $85M in Series C Financing | Silverback Therapeutics, Inc., a Seattle, WA-based clinical-stage biopharmaceutical company leveragi... | finsmes.co... |
| 23.09.2020 | Silverback Therapeutics nets $85M top-up to push lead ADC th... | After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-onc... | fiercebiot... |
| 23.09.2020 | Silverback Therapeutics nets $85M top-up to push lead ADC th... | After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-onc... | fiercebiot... |
| 11.03.2020 | Silverback Therapeutics Inks $78.5M in Series B | SEATTLE, WA, Silverback Therapeutics announced the close of an oversubscribed $78.5 million Series... | vcnewsdail... |
| 11.03.2020 | Silverback Therapeutics Raises $78.5 Million in Oversubscrib... | - | usvp.com/n... |
| 11.03.2020 | Silverback Therapeutics Raises $78.5M in Series B Financing | Silverback Therapeutics, a Seattle, WA-based biopharmaceutical company pioneering a new class of imm... | finsmes.co... |
Show more